Author + information
- Received March 12, 2008
- Revision received May 6, 2008
- Accepted May 12, 2008
- Published online September 9, 2008.
- Albert Schömig, MD⁎ (, )
- Julinda Mehilli, MD,
- Antoinette de Waha, MD,
- Melchior Seyfarth, MD,
- Jürgen Pache, MD and
- Adnan Kastrati, MD
- ↵⁎Reprint requests and correspondence:
Dr. Albert Schömig, Deutsches Herzzentrum München, Lazarettstrasse 36, 80636 Munich, Germany
Objectives This study assessed the impact on long-term mortality of percutaneous coronary intervention (PCI) versus medical treatment in patients with symptoms or signs of myocardial ischemia but no acute coronary syndrome.
Background The impact of PCI on the long-term prognosis of patients with stable coronary artery disease has not been established.
Methods We identified 17 randomized trials comparing a PCI-based invasive treatment strategy with medical treatment in 7,513 patients with symptoms or signs of myocardial ischemia but no acute coronary syndrome. Of these patients, 3,675 were assigned to the PCI group and 3,838 to the medical treatment group. The primary end point was all-cause death. The length of follow-up was in the range between 12 and 122 months, 51 months on average.
Results In the PCI group, 271 patients died compared with 335 patients in the medical treatment group, which corresponds to a 20% reduction in the odds ratio (OR) of all-cause death (OR: 0.80; 95% confidence interval [CI]: 0.64 to 0.99, p = 0.263 for heterogeneity across the trials). Allocation to the PCI group was associated with a nonsignificant 26% reduction in the OR of cardiac death (OR: 0.74, 95% CI: 0.51 to 1.06). In the PCI group, 319 patients had a nonfatal myocardial infarction after randomization compared with 357 patients in the medical treatment group (OR: 0.90, 95% CI: 0.66 to 1.23).
Conclusions These findings suggest that a PCI-based invasive strategy may improve long-term survival compared with a medical treatment-only strategy in patients with stable coronary artery disease.
Dr. Schömig has received unrestricted grant support for the Department of Cardiology, Technische Universität, from Amersham/General Electric, Bayerische Forschungsstiftung, Bristol-Myers Squibb, Cordis, Cryocath, Guidant, Medtronic, Nycomed, and Schering. Dr. Seyfarth has received lecture fees from Bristol-Myers Squibb, Lilly, and Sanofi-Aventis. Dr. Kastrati has received lecture fees from Bristol-Myers Squibb, Cordis, GlaxoSmithKline, Lilly, Medtronic, Novartis, and Sanofi-Aventis.
- Received March 12, 2008.
- Revision received May 6, 2008.
- Accepted May 12, 2008.
- American College of Cardiology Foundation